Blastic plasmacytoid dendritic cell neoplasm: A case report

Wang,Wei; Li,Wensheng; Jia,Jin‑Jing; Zheng,Yan; Wang,Hao; Gao,Xiao‑Min; Dong,Xin‑Yu; Tian,Qiong; Jing,Hui‑Ling; Wang,Xin; Xiao,Sheng‑Xiang

doi:10.3892/ol.2014.2836

Blastic plasmacytoid dendritic cell neoplasm: A case report

Authors:
- Wei Wang
- Wensheng Li
- Jin‑Jing Jia
- Yan Zheng
- Hao Wang
- Xiao‑Min Gao
- Xin‑Yu Dong
- Qiong Tian
- Hui‑Ling Jing
- Xin Wang
- Sheng‑Xiang Xiao
View Affiliations

Affiliations: Department of Dermatology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China, Department of Pathology, Third Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China
Published online on: December 29, 2014 https://doi.org/10.3892/ol.2014.2836
Pages: 1388-1392

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), formerly known as agranular cluster of differentiation (CD)4+/CD56+ hematodermic neoplasm, is a rare and aggressive type of lymphoma, with only ~100 cases reported worldwide. BPDCN is a hematological malignancy derived from precursors of plasmacytoid dendritic cells and is clinically characterized by cutaneous manifestations involving the lymph nodes and peripheral blood, a leukemia‑like dissemination and a poor prognosis. The present study reports the case of a 54‑year‑old male who presented with symptoms characteristic of BPDCN. Pathological and immunohistochemical analysis of abdominal skin lesion biopsies were used to determine a diagnosis of stage ⅢE BPDCN. Although cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy was administered, the patient succumbed to BPDCN nine days after the discontinuation of chemotherapy. Thus, the period from BPDCN presentation to mortality was ≤3 months. The case reported in the present study was characterized by rapid development and poor prognosis, and displayed additional features of BPDCN, including systemic dissemination and a short survival period.

View Figures

View References

1	Petrella T, Bagot M, Willemze R, et al: Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 123:662–675. 2005. View Article : Google Scholar : PubMed/NCBI
2	Adachi M, Maeda K, Takekawa M, et al: High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol. 47:278–282. 1994. View Article : Google Scholar : PubMed/NCBI
3	Chaperot L, Perrot I, Jacob MC, et al: Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur J Immunol. 34:418–426. 2004. View Article : Google Scholar : PubMed/NCBI
4	Boiocchi L, Lonardi S, Vermi W, Fisogni S and Facchetti F: BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoid dendritic cells. Blood. 122:296–297. 2013. View Article : Google Scholar : PubMed/NCBI
5	Burg G, Kempf W, Cozzio A, et al: WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol. 32:647–674. 2005. View Article : Google Scholar : PubMed/NCBI
6	Willemze R, Jaffe ES, Burg G, et al: WHO-EORTC classification for cutaneous lymphomas. Blood. 105:3768–3785. 2005. View Article : Google Scholar : PubMed/NCBI
7	Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J and Vardiman JW: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2. 4th edition. IARC Press; Lyon: 2008
8	Dalle S, Beylot-Barry M, Bagot M, et al: Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 162:74–79. 2010. View Article : Google Scholar
9	Foong HB, Chong M, Taylor EM, Carlson JA and Petrella T: Blastic plasmacytoid dendritic cell neoplasm in an elderly woman. Med J Malaysia. 68:161–163. 2013.PubMed/NCBI
10	Maio P, Fernandes C, Afonso A, Sachse F, Cabecadas J and Cardoso J: Case for diagnosis. An Bras Dermatol. 88:131–133. 2013. View Article : Google Scholar : PubMed/NCBI
11	Garnache-Ottou F, Chaperot L, Biichle S, et al: Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood. 105:1256–1264. 2005. View Article : Google Scholar
12	Eichenauer D, Engert A, Diehl V, et al: Hodgkin lymphoma: clinical manifestations, staging, and therapy. Hematology: Basic Principles and Practice. Hoffman R, Benz EJ, Leslie E and Silberstein LE: 6th edition. Elsevier; Saunder, Philadelphia, PA: pp. 1138–1156. 2013
13	Kaushansky K, Lichtman MA, Beutler E, et al: General Considerations of Lymphoma: Epidemiology, Etiology, Heterogeneity, and Primary Extranodel Disease. William’s Hematology. 8th edition. McGraw-Hill Medical; New York, NY: pp. 1497–1510. 2010
14	Macon WR, McCurley TL, Kurtin PJ and Dogan A: Lymphoproliferative disorders. Wintrobe’s Clinical Hematology. Wintrobe MM and Greer JP: 12th edition. Lippincott Williams & Wilkins; Philadelphia, PA: pp. 2017–2311. 2009
15	Wiesner T, Obenauf AC, Cota C, Fried I, Speicher MR and Cerroni L: Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms. J Invest Dermatol. 130:1152–1157. 2010. View Article : Google Scholar
16	Bilbao EA, Chirife AM, Florio D, Gimenez LB, Marino L and Rosso DA: Hematodermic CD4⁺ CD56⁺ neoplasm in childhood. Medicina (B Aires). 68:147–150. 2008.(In Spanish).
17	Marafioti T, Paterson JC, Ballabio E, et al: Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood. 111:3778–3792. 2008. View Article : Google Scholar : PubMed/NCBI
18	Dzionek A, Inagaki Y, Okawa K, et al: Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol. 63:1133–1148. 2002. View Article : Google Scholar : PubMed/NCBI
19	Lencastre A, Cabete J, João A, Farinha P, Ferreira G and Lestre S: Blastic plasmacytoid dendritic cell neoplasm. An Bras Dermatol. 88(6 Suppl 1): 158–161. 2013. View Article : Google Scholar : PubMed/NCBI
20	Shi Y and Wang E: Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review. Arch Pathol Lab Med. 138:564–569. 2014. View Article : Google Scholar : PubMed/NCBI
21	Riaz W, Zhang L, Horna P and Sokol L: Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control. 21:279–289. 2014.PubMed/NCBI
22	Julia F, Dalle S, Duru G, et al: Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol. 38:673–680. 2014. View Article : Google Scholar : PubMed/NCBI
23	Cota C, Vale E, Viana I, et al: Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 34:75–87. 2010. View Article : Google Scholar
24	Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA and Hamadani M: Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 19:1006–1012. 2013. View Article : Google Scholar : PubMed/NCBI
25	Suzuki R, Nakamura S, Suzumiya J, et al: Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor). Cancer. 104:1022–1031. 2005. View Article : Google Scholar : PubMed/NCBI
26	Jegalian AG, Buxbaum NP, Facchetti F, et al: Blastic plasmacytoid dendritic cell neoplasm in the pediatric population: diagnostic features and clinical implications. Haematologica. 95:1873–1879. 2010. View Article : Google Scholar : PubMed/NCBI